alxoncology.com (ALXO): Price-to-Projected Revenue Ratio

ALXO (ALX Oncology Holdings Inc.) - company brandmark

ALX Oncology Holdings (ALXO) previously funded clinical trials using existing cash reserves. The forward P/S ratio demonstrates the current market valuation, where the value reflects the metric's balance. Looking ahead, the safe drug evorpacept will provide a competitive edge in cancer therapy, while the unique method of blocking tumor signals will create the conditions for establishing significant pricing power.

ALXO ALX Oncology Holdings Inc.: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 11/18/2026

Analytical breakdowns for ALX Oncology (ALXO)

- stock price and consensus target price:
- stock exchange capitalization data:
Summary company analysis:alxoncology.com ALXO
Manufactured products of alxoncology.com

For the non-cyclical biotech ALX Oncology Holdings (ALXO), whose value depends on scientific data rather than GDP, this indicator reflects the market value of every dollar of expected revenue. By analyzing the forward P/S ratio, an investor determines the degree of overpayment for future sales relative to historical averages, which allows for identifying an entry point with a margin of safety and minimizing the risks of capital freeze.

Competitor analysis

ImmunityBio Inc - Forward Price-to-Revenue Multiple|Forward P/S Multiple Immunocore Corp IMCR|JANX - Price-to-Projected Revenue Ratio|RCUS (arcusbio.com) - Market Cap to Projected Revenue|Zymeworks Biopharmaceuticals (ZYME) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Tango Pharma (TNGX)|Forward Price-to-Revenue Multiple IOVA|IMTX - Projected Price to Revenue|Forward Price-to-Revenue Multiple XNCR (Xencor Corp)|Price to Expected Revenue Ratio CMPX|Forward P/S Multiple REPL (Replimune)|Forward Price to Sales LYEL|innate-pharma.com - Forward P/S Multiple|Market Cap to Future Revenue Ratio Pyxis Oncology|Compugen Limited (CGEN) - Price-to-Projected Revenue Ratio|IO Biotech, Inc. - Forward Price to Sales|STRO (sutrobio.com) - Forward P/S Multiple|Forward P/S Multiple MiNK Therapeutics Inc.|Price-to-Projected Revenue Ratio werewolftx.com (HOWL)|IMMX: Future Price to Revenue|Forward P/S Multiple CUE (Cue Biopharma Inc.)|PDS Biotechnology (PDSB) - Market Cap to Future Revenue Ratio|SONN - Price-to-Projected Revenue Ratio|MAIA Biotechnology, Inc. (MAIA) - Forward Price-to-Revenue Multiple|LIMN: Forward P/S Multiple|LAVA Therapeutics N.V. (LVTX) - Forward P/S Multiple|Forward Price-to-Revenue Multiple NXTC|Forward P/S Multiple leaptx.com|Forward P/S Multiple INTS|Market Cap to Expected Sales Ratio Sensei Biotherapeutics, Inc.|Forward P/S Multiple TOVX (Theriva Corp)|Market Cap to Expected Sales Ratio gritstonebio.com (GRTS)|kinetabio.com - Forward P/S Multiple|NexImmune (NEXI) - Forward Price-to-Revenue Multiple|turnstonebio.com (TSBX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Vaccinex, Inc (VCNX)|Forward Price-to-Revenue Multiple HARP